EP. 6A: Benefits of Using Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer in Clinical Practice

EP: 1.EP. 1: Extensive-Stage Small Cell Lung Cancer Treatment Landscape

EP: 2.EP. 2A: Treatment Challenges and Unmet Needs in Extensive-Stage Small Cell Lung Cancer

EP: 3.EP. 2B: Challenges Affecting the Management of Extensive-Stage Small Cell Lung Cancer

EP: 4.EP. 3: Management of Extensive-Stage Small Cell Lung Cancer Treatment-Related Events

EP: 5.EP. 4A: The Role of Trilaciclib in the Management of Chemotherapy-Induced Myelosuppression in SCLC

EP: 6.EP. 4B: Considering Chemotherapy-Induced Myelosuppression and the Impact of Trilaciclib on Its Management

EP: 7.EP. 5: Clinical Trial Evidence for the Myeloprotective Benefit of Trilaciclib for Chemotherapy-Induced Myelosuppression

Now Viewing

EP: 8.EP. 6A: Benefits of Using Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer in Clinical Practice

EP: 9.EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer

EP: 10.EP. 7: Clinical Trial Evidence for Chemoprotectant Benefit of ALRN-6924 for Chemotherapy-Induced Myelosuppression

EP: 11.EP. 8A: Considerations for Reactive and Proactive Approaches to the Management of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

EP: 12.EP. 8B: Reactive and Proactive Treatment Approaches for the Management of Chemotherapy-Induced Myelosuppression

EP: 13.EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial Data

EP: 14.EP. 10A: Impact of Trilaciclib on Chemotherapy-Induced Myelosuppression in Patients with ES-SCLC

EP: 15.Episode 10B: Impact of Trilaciclib on Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC

EP: 16.Episode 11A: Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment

EP: 17.Episode 11B: The Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment

EP: 18.EP 12A: Managing Thrombocytopenia in Patients receiving Chemotherapy for ES-SCLC

EP: 19.EP 12B: Management of Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC

Trilaciclib was approved in 2021 for the treatment of patients with extensive-stage small-cell lung cancer who are receiving chemotherapy with either platinum-etoposide or topotecan. Through the approval of this drug, we now have an option to prevent chemotherapy-related myelosuppression in these patients, not just for preventing neutropenia but also anemia and thrombocytopenia because trilaciclib impacts and targets trilineage hematopoiesis, which is a big advantage.

The schedule of trilaciclib recommends that the drug is given intravenously on the same day that patients are getting chemotherapy. Patients don't have to come to clinic for additional visits. They get their treatments with this drug [on the] same day as their pre-planned trips for the other agents. The drug is relatively well-tolerated.

In patients who are at high risk for myelosuppression, such as elderly patients, such as patients who already have lower blood counts even before starting treatment because of tumor enrollment in their bone marrow, I strongly consider this drug. We also consider this drug in patients who are refractory to G-CSF (granulocyte colony-stimulating factor) during cycle 1.

The most significant benefit I would say is in terms of fewer treatment delays and interruptions and the ability to give full doses of chemotherapy to these patients, which is very crucial because small cell lung can cancer is an aggressive form of lung cancer, and we want to give patients as much of their plan treatment as possible at the optimum doses.